Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin, Fludarabine, and Cytarabine in Relapsed AML/MDS
NCT00480987Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2007
- Primary completion
- Aug 2010
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Number of Participants With Objective Response at 2 months. Started Jul 2007; status: terminated.
02
Drugs
oxaliplatin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00480987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00480987.